Free Trial
NYSE:BIO

Bio-Rad Laboratories (BIO) Stock Price, News & Analysis

Bio-Rad Laboratories logo
$331.39 +0.86 (+0.26%)
(As of 05:30 PM ET)

About Bio-Rad Laboratories Stock (NYSE:BIO)

Key Stats

Today's Range
$328.35
$332.34
50-Day Range
$313.15
$374.28
52-Week Range
$262.12
$387.99
Volume
60,566 shs
Average Volume
240,632 shs
Market Capitalization
$9.28 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$394.20
Consensus Rating
Moderate Buy

Company Overview

Bio-Rad Laboratories, Inc. manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets. It also designs, manufactures, markets, and supports test systems, informatics systems, test kits, and specialized quality controls for hospitals, diagnostic reference, transfusion, and physician office laboratories. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.

Bio-Rad Laboratories Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
79th Percentile Overall Score

BIO MarketRank™: 

Bio-Rad Laboratories scored higher than 79% of companies evaluated by MarketBeat, and ranked 232nd out of 945 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Bio-Rad Laboratories has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on 3 buy ratings, 2 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Bio-Rad Laboratories has only been the subject of 2 research reports in the past 90 days.

  • Read more about Bio-Rad Laboratories' stock forecast and price target.
  • Earnings Growth

    Earnings for Bio-Rad Laboratories are expected to grow by 11.95% in the coming year, from $10.29 to $11.52 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Bio-Rad Laboratories is -12.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Bio-Rad Laboratories is -12.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Bio-Rad Laboratories has a P/B Ratio of 1.08. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    2.88% of the float of Bio-Rad Laboratories has been sold short.
  • Short Interest Ratio / Days to Cover

    Bio-Rad Laboratories has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Bio-Rad Laboratories has recently increased by 12.89%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Bio-Rad Laboratories does not currently pay a dividend.

  • Dividend Growth

    Bio-Rad Laboratories does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    2.88% of the float of Bio-Rad Laboratories has been sold short.
  • Short Interest Ratio / Days to Cover

    Bio-Rad Laboratories has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Bio-Rad Laboratories has recently increased by 12.89%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Bio-Rad Laboratories has a news sentiment score of 0.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.62 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 12 news articles for Bio-Rad Laboratories this week, compared to 6 articles on an average week.
  • Search Interest

    Only 2 people have searched for BIO on MarketBeat in the last 30 days. This is a decrease of -82% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Bio-Rad Laboratories insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    17.06% of the stock of Bio-Rad Laboratories is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    65.24% of the stock of Bio-Rad Laboratories is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Bio-Rad Laboratories' insider trading history.
Receive BIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bio-Rad Laboratories and its competitors with MarketBeat's FREE daily newsletter.

BIO Stock News Headlines

Zacks Research Brokers Decrease Earnings Estimates for BIO
What is Zacks Research's Forecast for BIO FY2024 Earnings?
Why I'm telling friends to avoid gold stocks
Back in November, gold made a tiny move of 1.6%. But according to my backtesting by using a special type of gold trade, I would have seen a 141% gain in just a week. It happened again in March. Gold nudged up 1.2%. This time? A 104% overnight gain. And in June? A 1% gold move turned into a 74% gain in two weeks. Granted, there would have been smaller wins and those that did not work out, but you see, there's a reason I'm telling all my friends to hold off from buying gold or regular gold stocks right now. There's a more lucrative way to play the gold market as we enter a new breakout period. It's all about catching what I call "Acceleration Cycles."
Bio-Rad Laboratories Inc. - Ordinary Shares - Class A
See More Headlines

BIO Stock Analysis - Frequently Asked Questions

Bio-Rad Laboratories' stock was trading at $322.89 at the start of the year. Since then, BIO stock has increased by 2.6% and is now trading at $331.39.
View the best growth stocks for 2024 here
.

Bio-Rad Laboratories, Inc. (NYSE:BIO) released its quarterly earnings results on Wednesday, October, 30th. The medical research company reported $2.01 EPS for the quarter, beating analysts' consensus estimates of $1.16 by $0.85. The firm's quarterly revenue was up 2.8% compared to the same quarter last year.
Read the conference call transcript
.

Bio-Rad Laboratories subsidiaries include Dropworks Inc., Celsee, Raindance Technologies Limited, GnuBIO Inc., Bio-Rad AbD Serotec GmbH, Propel Labs - Cell Sorting System Division, QuantaLife, and more.

Bio-Rad Laboratories' top institutional investors include Van ECK Associates Corp (4.57%), Veritas Asset Management LLP (3.81%), State Street Corp (2.27%) and UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC (1.58%). Insiders that own company stock include Andrew J Last, Michael Crowley, Timothy S Ernst, Dara Wright, James Barry and Ajit Ramalingam.
View institutional ownership trends
.

Shares of BIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Bio-Rad Laboratories investors own include Humana (HUM), American Water Works (AWK), Waste Connections (WCN), Voyager Therapeutics (VYGR), The RMR Group (RMR), DiamondRock Hospitality (DRH) and AUO (AUOTY).

Company Calendar

Last Earnings
10/30/2024
Today
12/26/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Analytical instruments
Sub-Industry
Life Sciences Tools & Services
CUSIP
09057220
Employees
8,030
Year Founded
1952

Price Target and Rating

Average Stock Price Target
$394.20
High Stock Price Target
$481.00
Low Stock Price Target
$315.00
Potential Upside/Downside
+19.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.60
Research Coverage
5 Analysts

Profitability

Net Income
$-637,320,000.00
Pretax Margin
-38.96%

Debt

Sales & Book Value

Annual Sales
$2.58 billion
Cash Flow
$11.75 per share
Book Value
$306.51 per share

Miscellaneous

Free Float
23,221,000
Market Cap
$9.28 billion
Optionable
Optionable
Beta
0.90

Social Links

The Best High-Yield Dividend Stocks for 2024 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

This page (NYSE:BIO) was last updated on 12/26/2024 by MarketBeat.com Staff
From Our Partners